Eμ-BRD2 transgenic mice develop B-cell lymphoma and leukemia

Rebecca J. Greenwald, Joseph R. Tumang, Anupama Sinha, Nicolas Currier, Robert Cardiff, Thomas L. Rothstein, Douglas V. Faller, Gerald V. Denis

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Transgenic mice with lymphoid-restricted overexpression of the double bromodomain protein bromodomain-containing 2 (Brd2) develop splenic B-cell lymphoma and, upon transplantation, B-cell leukemia with leukemic infiltrates in liver and lung. Brd2 is a nuclear-localized transcription factor kinase that is most closely related to TATA box binding protein-associated factor, 250 kDa (TAFII250) and the Drosophila developmental protein female sterile homeotic. Constitutive expression of BRD2 in the lymphoid compartment increases cyclin A transcription, "priming" transgenic B cells for proliferation. Mice stochastically develop an aggressive B-cell lymphoma with the features of B-1 cells, including CD5 and surface IgM expression. The B-cell lymphoma is monoclonal for immunoglobulin gene rearrangement and is phenotypically stable. The lymphoblasts are very large and express a transcriptome that is similar to human non-Hodgkin lymphomas. Both a wild-type BRD2 transgene and a kinase-null point mutant drive lymphomagenesis; therefore we propose that, rather than kinase activity, Brd2-mediated recruitment of E2 promoter binding factors (E2Fs) and a specific histone acetyltransferase to the cyclin A promoter by both types of transgene is a mechanistic basis for neoplasia. This report is the first to describe a transgenic mouse model for constitutive expression of a protein with more than one bromodomain.

Original languageEnglish (US)
Pages (from-to)1475-1484
Number of pages10
JournalBlood
Volume103
Issue number4
DOIs
StatePublished - Feb 15 2004
Externally publishedYes

Fingerprint

B-Cell Leukemia
B-Cell Lymphoma
Transgenic Mice
Cyclin A
Phosphotransferases
Cells
Transgenes
TATA-Box Binding Protein
Histone Acetyltransferases
Immunoglobulin Genes
Gene Rearrangement
Transcriptome
Non-Hodgkin's Lymphoma
Immunoglobulin M
Proteins
B-Lymphocytes
Transcription Factors
Transplantation
Cell Proliferation
Transcription

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Greenwald, R. J., Tumang, J. R., Sinha, A., Currier, N., Cardiff, R., Rothstein, T. L., ... Denis, G. V. (2004). Eμ-BRD2 transgenic mice develop B-cell lymphoma and leukemia. Blood, 103(4), 1475-1484. https://doi.org/10.1182/blood-2003-06-2116

Eμ-BRD2 transgenic mice develop B-cell lymphoma and leukemia. / Greenwald, Rebecca J.; Tumang, Joseph R.; Sinha, Anupama; Currier, Nicolas; Cardiff, Robert; Rothstein, Thomas L.; Faller, Douglas V.; Denis, Gerald V.

In: Blood, Vol. 103, No. 4, 15.02.2004, p. 1475-1484.

Research output: Contribution to journalArticle

Greenwald, RJ, Tumang, JR, Sinha, A, Currier, N, Cardiff, R, Rothstein, TL, Faller, DV & Denis, GV 2004, 'Eμ-BRD2 transgenic mice develop B-cell lymphoma and leukemia', Blood, vol. 103, no. 4, pp. 1475-1484. https://doi.org/10.1182/blood-2003-06-2116
Greenwald RJ, Tumang JR, Sinha A, Currier N, Cardiff R, Rothstein TL et al. Eμ-BRD2 transgenic mice develop B-cell lymphoma and leukemia. Blood. 2004 Feb 15;103(4):1475-1484. https://doi.org/10.1182/blood-2003-06-2116
Greenwald, Rebecca J. ; Tumang, Joseph R. ; Sinha, Anupama ; Currier, Nicolas ; Cardiff, Robert ; Rothstein, Thomas L. ; Faller, Douglas V. ; Denis, Gerald V. / Eμ-BRD2 transgenic mice develop B-cell lymphoma and leukemia. In: Blood. 2004 ; Vol. 103, No. 4. pp. 1475-1484.
@article{0d978aba6d2448feb1784d08b49f71fc,
title = "Eμ-BRD2 transgenic mice develop B-cell lymphoma and leukemia",
abstract = "Transgenic mice with lymphoid-restricted overexpression of the double bromodomain protein bromodomain-containing 2 (Brd2) develop splenic B-cell lymphoma and, upon transplantation, B-cell leukemia with leukemic infiltrates in liver and lung. Brd2 is a nuclear-localized transcription factor kinase that is most closely related to TATA box binding protein-associated factor, 250 kDa (TAFII250) and the Drosophila developmental protein female sterile homeotic. Constitutive expression of BRD2 in the lymphoid compartment increases cyclin A transcription, {"}priming{"} transgenic B cells for proliferation. Mice stochastically develop an aggressive B-cell lymphoma with the features of B-1 cells, including CD5 and surface IgM expression. The B-cell lymphoma is monoclonal for immunoglobulin gene rearrangement and is phenotypically stable. The lymphoblasts are very large and express a transcriptome that is similar to human non-Hodgkin lymphomas. Both a wild-type BRD2 transgene and a kinase-null point mutant drive lymphomagenesis; therefore we propose that, rather than kinase activity, Brd2-mediated recruitment of E2 promoter binding factors (E2Fs) and a specific histone acetyltransferase to the cyclin A promoter by both types of transgene is a mechanistic basis for neoplasia. This report is the first to describe a transgenic mouse model for constitutive expression of a protein with more than one bromodomain.",
author = "Greenwald, {Rebecca J.} and Tumang, {Joseph R.} and Anupama Sinha and Nicolas Currier and Robert Cardiff and Rothstein, {Thomas L.} and Faller, {Douglas V.} and Denis, {Gerald V.}",
year = "2004",
month = "2",
day = "15",
doi = "10.1182/blood-2003-06-2116",
language = "English (US)",
volume = "103",
pages = "1475--1484",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "4",

}

TY - JOUR

T1 - Eμ-BRD2 transgenic mice develop B-cell lymphoma and leukemia

AU - Greenwald, Rebecca J.

AU - Tumang, Joseph R.

AU - Sinha, Anupama

AU - Currier, Nicolas

AU - Cardiff, Robert

AU - Rothstein, Thomas L.

AU - Faller, Douglas V.

AU - Denis, Gerald V.

PY - 2004/2/15

Y1 - 2004/2/15

N2 - Transgenic mice with lymphoid-restricted overexpression of the double bromodomain protein bromodomain-containing 2 (Brd2) develop splenic B-cell lymphoma and, upon transplantation, B-cell leukemia with leukemic infiltrates in liver and lung. Brd2 is a nuclear-localized transcription factor kinase that is most closely related to TATA box binding protein-associated factor, 250 kDa (TAFII250) and the Drosophila developmental protein female sterile homeotic. Constitutive expression of BRD2 in the lymphoid compartment increases cyclin A transcription, "priming" transgenic B cells for proliferation. Mice stochastically develop an aggressive B-cell lymphoma with the features of B-1 cells, including CD5 and surface IgM expression. The B-cell lymphoma is monoclonal for immunoglobulin gene rearrangement and is phenotypically stable. The lymphoblasts are very large and express a transcriptome that is similar to human non-Hodgkin lymphomas. Both a wild-type BRD2 transgene and a kinase-null point mutant drive lymphomagenesis; therefore we propose that, rather than kinase activity, Brd2-mediated recruitment of E2 promoter binding factors (E2Fs) and a specific histone acetyltransferase to the cyclin A promoter by both types of transgene is a mechanistic basis for neoplasia. This report is the first to describe a transgenic mouse model for constitutive expression of a protein with more than one bromodomain.

AB - Transgenic mice with lymphoid-restricted overexpression of the double bromodomain protein bromodomain-containing 2 (Brd2) develop splenic B-cell lymphoma and, upon transplantation, B-cell leukemia with leukemic infiltrates in liver and lung. Brd2 is a nuclear-localized transcription factor kinase that is most closely related to TATA box binding protein-associated factor, 250 kDa (TAFII250) and the Drosophila developmental protein female sterile homeotic. Constitutive expression of BRD2 in the lymphoid compartment increases cyclin A transcription, "priming" transgenic B cells for proliferation. Mice stochastically develop an aggressive B-cell lymphoma with the features of B-1 cells, including CD5 and surface IgM expression. The B-cell lymphoma is monoclonal for immunoglobulin gene rearrangement and is phenotypically stable. The lymphoblasts are very large and express a transcriptome that is similar to human non-Hodgkin lymphomas. Both a wild-type BRD2 transgene and a kinase-null point mutant drive lymphomagenesis; therefore we propose that, rather than kinase activity, Brd2-mediated recruitment of E2 promoter binding factors (E2Fs) and a specific histone acetyltransferase to the cyclin A promoter by both types of transgene is a mechanistic basis for neoplasia. This report is the first to describe a transgenic mouse model for constitutive expression of a protein with more than one bromodomain.

UR - http://www.scopus.com/inward/record.url?scp=0842264007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0842264007&partnerID=8YFLogxK

U2 - 10.1182/blood-2003-06-2116

DO - 10.1182/blood-2003-06-2116

M3 - Article

C2 - 14563639

AN - SCOPUS:0842264007

VL - 103

SP - 1475

EP - 1484

JO - Blood

JF - Blood

SN - 0006-4971

IS - 4

ER -